Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Essential Healthcare News.
Press releases published on April 22, 2025
Aveanna to Participate at the Bank of America Securities 2025 Health Care Conference
GlobeNewswire
·
April 22, 2025
ATLANTA, April 22, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Bank of America Securities 2025 Health Care Conference in Las Vegas on May 14, 2025. Management …
BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)
GlobeNewswire
·
April 22, 2025
Over 75 patients enrolled in BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancer (MBC) 54 clinical sites across 15 states currently enrolling patients including Sylvester Comprehensive Cancer Center, …
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET
GlobeNewswire
·
April 22, 2025
PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its first quarter …
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
GlobeNewswire
·
April 22, 2025
Fifth issued patent in the U.S. for QTORIN™ rapamycin with anticipated patent life extending into 2038 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care for microcystic lymphatic malformations in the U.S. WAYNE, Pa., …
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference
GlobeNewswire
·
April 22, 2025
CHASKA, Minn., April 22, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming CDMO …
EDAP Announces Significant Presence of Focal One® at the Upcoming 120th American Urological Association (AUA) Annual Meeting
GlobeNewswire
·
April 22, 2025
Activities to include expert-led demonstrations, semi-live Focal One procedures and hands-on simulations Final results of randomized clinical trial (FARP Study) comparing ultrasound-based focal ablation versus radical prostatectomy as a first-line …
PolyPid to Participate in The Citizens Life Sciences Conference
GlobeNewswire
·
April 22, 2025
PETACH TIKVA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will participate in a …
Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025
GlobeNewswire
·
April 22, 2025
ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 first quarter on …
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader
GlobeNewswire
·
April 22, 2025
Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June 2025 Two parallel Phase 2b trials in AD and asthma …
InStride’s Hybrid Clinical Cohorts Fill High-Need Roles in Healthcare
GlobeNewswire
·
April 22, 2025
LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- InStride, a human capital management company providing strategic education benefits, today announced a hybrid education model that empowers healthcare organizations to fill critical roles by developing talent …
Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025
GlobeNewswire
·
April 22, 2025
SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. The company will host a conference …
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy
GlobeNewswire
·
April 22, 2025
Breakthrough Device Designation (“BDD”) applies to an estimated U.S. population of over 7.7 million patients with uncontrolled hypertension and increased cardiovascular risk BDD also encompasses pacemaker-indicated patients with uncontrolled hypertension …
Rapport Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
·
April 22, 2025
BOSTON and SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for …
Medicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire
·
April 22, 2025
TORONTO and HOUSTON, April 22, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune …
Axsome Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
·
April 22, 2025
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in four upcoming …
Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody
GlobeNewswire
·
April 22, 2025
- Initiation of Upcoming Phase 1a/1b Clinical Trial Expected in the Second Quarter of 2025 - WAYNE, Pa, April 22, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel …
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
GlobeNewswire
·
April 22, 2025
TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network (UHN) Research Ethics Board has granted approval for Toronto General …
BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025
GlobeNewswire
·
April 22, 2025
MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additionally, the Company will host a conference call and …
BioNTech veröffentlicht am 5. Mai 2025 Ergebnisse für das erste Quartal 2025 und informiert über operativen Fortschritt
GlobeNewswire
·
April 22, 2025
MAINZ, Deutschland, 22. April 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Montag, den 5. Mai 2025, die Ergebnisse für das erste Quartal 2025 veröffentlichen. Darüber hinaus wird das Unternehmen am selben …
Amesite Announces NurseMagic™ Meets HIPAA Requirements for Individuals Users, in Addition to Enterprises
GlobeNewswire
·
April 22, 2025
DETROIT, April 22, 2025 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a leading technology company specializing in the development and marketing of B2C and B2B AI-driven solutions, today announced NurseMagic™ now meets HIPAA requirements for all users. …